首页> 外文期刊>Research in social & administrative pharmacy: RSAP >Identifying early prescribers of cycloxygenase-2 inhibitors (COX-2s) in Nova Scotia, Canada: Considerations for targeted academic detailing.
【24h】

Identifying early prescribers of cycloxygenase-2 inhibitors (COX-2s) in Nova Scotia, Canada: Considerations for targeted academic detailing.

机译:确定加拿大新斯科舍省环氧合酶2抑制剂(COX-2s)的早期处方者:针对性学术细节的考虑。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Expenditures on prescribed drugs in Canada are now well past those for all services provided by outpatient physicians (Dollars 26.9 billion vs. Dollars 21.5 billion in 2007). Government has the opportunity to dedicate resources to continuing medical education of physicians, and effective profiling would assist in the allocation of these educational resources. OBJECTIVE: The purpose of this study was to evaluate physician prescribing patterns and establish criteria by which various prescribing profiles may be segmented and identified, so as to better target detailing and continuing medical education resources. METHODS: A sample of 925 physicians practicing in Nova Scotia (NS) was characterized by age, sex, rural/urban nature of their practice and specialty. They were subsequently evaluated relative to all prescriptions filled by their patients who were beneficiaries of the NS Department of Health's senior's Pharmacare drug insurance program. The adoption of COX-2 inhibitors (eg, Vioxx) and Celebrex) and their substitution for NS-NSAIDs (non-specific non-steroidal anti-inflammatory drugs, eg, Motrin) from 1999 to 2003 were examined. RESULTS: This analysis established the profiles of 2 key groups of physicians. The first consisted of those most likely to comprise the early, high volume COX-2-prescribing universe (profiles based on the absolute number of prescriptions written over a given period). These individuals were likely to be older, more experienced, male general practitioners operating in a rural practice. The second group consisted of those most likely to comprise the early, high-relative, COX-2-prescribing universe (prescribing of COX-2s relative to non-selective, non-steroidal anti-inflammatory drugs (NS-NSAIDs)). These individuals were likely to be younger, less experienced female general practitioners, operating in an urban practice. CONCLUSION: This research moves us closer to identifying unique physician segments that account for either the largest volume of prescriptions for new drugs, or the largest relative volume of prescriptions. Use of these physician groups can help continuing medical education providers target specific prescribers with information to assist them in examining and improving their prescribing.
机译:背景:加拿大处方药的支出现在已经远远超出了门诊医生提供的所有服务的支出(2006年为269亿美元,而2007年为215亿美元)。政府有机会将资源专用于继续对医生进行医学教育,而有效的资料分析将有助于分配这些教育资源。目的:本研究的目的是评估医师的处方模式并建立标准,从而可以分割和识别各种处方概况,从而更好地针对详细信息和继续进行医学教育资源。方法:通过在新斯科舍省(NS)执业的925名医生的样本,按其年龄,性别,所从事业务和专业的农村/城市性质进​​行了特征分析。随后,根据其由NS卫生部上级Pharmacare药物保险计划的受益人填写的所有处方对他们进行评估。从1999年到2003年,研究了COX-2抑制剂(例如Vioxx和Celebrex)的采用及其对NS-NSAIDs(非特异性非甾体抗炎药,例如Motrin)的替代作用。结果:这项分析建立了两个关键医师组的概况。第一个由最有可能构成早期大量COX-2处方药的药物组成(基于给定时期内处方绝对数量的配置文件)。这些人可能是年龄较大,经验丰富的男性全科医生,在农村从事手术。第二组由最有可能包括早期,相对高,处方COX-2的人群(处方相对于非选择性,非甾体类抗炎药(NS-NSAID)的COX-2处方)组成。这些人可能是年轻的,经验不足的女性全科医生,从事城市实践。结论:这项研究使我们更接近于确定独特的医师细分市场,这些细分市场占新药处方的最大量或处方的最大相对量。这些医师小组的使用可以帮助继续医学教育提供者针对特定处方者提供信息,以帮助他们检查和改进处方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号